NLRP3 and Parkinson disease: Clinical evidence obtained, via post-mortem examinations of PD patients’ brains, also showed increased NLRP3 inflammasome expression and activation at the substantia nigra where dopaminergic neuronal loss has occurred (Gordon et al., 2018; von Herrmann et al., 2018; Anderson et al., 2021).